Discovery of novel drugs for promising targets.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Therapeutics

• Publication date

  2013-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.clinthera.2013.08.005PMID 24054704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The clinical relevance of cancer cell lines.

  2013cited by this paper
• Managing missing measurements in small-molecule screens

  2013cited by this paper
• An informatic pipeline for managing high-throughput screening experiments and analyzing data from stereochemically diverse libraries

  2013cited by this paper
• siRNA delivery: from basics to therapeutic applications.

  2013cited by this paper
• Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• From integrative genomics to therapeutic targets.

  2013cited by this paper
• Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach.

  2013cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cited by this paper
• Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

  2012cited by this paper
• Structural biology and drug discovery for protein-protein interactions.

  2012cited by this paper
• Kinase-Kernel Models: Accurate In silico Screening of 4 Million Compounds Across the Entire Human Kinome

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research.

  2012cited by this paper
• Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Patient-derived tumour xenografts as models for oncology drug development

  2012cited by this paper
• Targeting protein-protein interactions and fragment-based drug discovery.

  2012cited by this paper
• Predictive cheminformatics in drug discovery: statistical modeling for analysis of micro-array and gene expression data.

  2012cited by this paper
• The multicellular tumor spheroid model for high-throughput cancer drug discovery

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Chemogenomics in drug discovery: computational methods based on the comparison of binding sites.

  2012cited by this paper
• Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.

  2012cited by this paper
• Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Genetic interactions in cancer progression and treatment.

  2011cited by this paper
• 20 years of DNA-encoded chemical libraries.

  2011cited by this paper
• A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

  2011cited by this paper
• 3D tumour models: novel in vitro approaches to cancer studies

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Current trends in virtual high throughput screening using ligand-based and structure-based methods.

  2011cited by this paper
• Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

  2011cited by this paper
• Fragment-based drug design: computational & experimental state of the art.

  2011cited by this paper
• Cancer therapy based on oncogene addiction

  2011cited by this paper
• ICH S9

  2011cited by this paper
• Small-molecule discovery from DNA-encoded chemical libraries.

  2011cited by this paper
• Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.

  2010cited by this paper
• The translatability of animal models for clinical development: biomarkers and disease models.

  2010cited by this paper
• SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison

  2010cited by this paper
• The challenge of selecting the 'right' in vivo oncology pharmacology model.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• The use of web ontology languages and other semantic web tools in drug discovery

  2010cited by this paper
• Binding Affinity Prediction with Property-Encoded Shape Distribution Signatures

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Predicting Polypharmacology by Binding Site Similarity: From Kinases to the Protein Universe

  2010cited by this paper
• Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

  2010cited by this paper
• Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

  2009cited by this paper
• Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

  2009cited by this paper
• Shifting paradigms: the seeds of oncogene addiction

  2009cited by this paper
• Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• LigMatch: A Multiple Structure-Based Ligand Matching Method for 3D Virtual Screening

  2009cited by this paper
• AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data

  2008cited by this paper
• Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP).

  2008cited by this paper
• High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.

  2008cited by this paper
• Universal strategies in research and drug discovery based on protein-fragment complementation assays

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Towards drugs targeting multiple proteins in a systems biology approach.

  2007cited by this paper
• Chemogenomic approaches to drug discovery: similar receptors bind similar ligands

  2007cited by this paper
• Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

  2007cited by this paper
• Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

  2007cited by this paper
• Mouse Modeling in Oncologic Preclinical and Translational Research

  2006cited by this paper
• Tumor models for efficacy determination

  2006cited by this paper
• Chemometric Analysis of Ligand Receptor Complementarity: Identifying Complementary Ligands Based on Receptor Information (CoLiBRI)

  2006cited by this paper
• A critical assessment of docking programs and scoring functions.

  2006cited by this paper
• Mouse models in oncogenesis and cancer therapy

  2006cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Development and characterization of efficient xenograft models for benign and malignant human prostate tissue

  2005cited by this paper
• Technological Advances in High-Throughput Screening

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Chemogenomics: an emerging strategy for rapid target and drug discovery

  2004cited by this paper
• High-throughput screening: new technology for the 21st century.

  2000cited by this paper
• Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.

  1987cited by this paper
• Heterotransplantation of human head and neck tumours into nude mice.

  1983cited by this paper

• Multitargeted pharmacokinetics, molecular docking and network pharmacology-based identification of effective phytocompounds from Sauropus androgynus (L.) Merr for inflammation and cancer treatment

  2023cites this paper
• Assessments of Alpha-Amylase Inhibitory Potential of Tagetes Flavonoids through In Vitro, Molecular Docking, and Molecular Dynamics Simulation Studies

  2023cites this paper
• Indazole-based microtubule-targeting agents as potential candidates for anticancer drugs discovery.

  2022cites this paper
• Anti-Cancer Drug Solubility Development within a Green Solvent: Design of Novel and Robust Mathematical Models Based on Artificial Intelligence

  2022cites this paper
• In Silico Molecular Docking Analysis of Karanjin against Alzheimer’s and Parkinson’s Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy

  2022cites this paper
• Involvement of a Novel Organic Cation Transporter in Paeonol Transport Across the Blood-Brain Barrier

  2019cites this paper
• Leukemia Cell Cycle Chemical Profiling Identifies the G2-Phase Leukemia Specific Inhibitor Leusin-1.

  2019cites this paper
• Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.

  2017cites this paper
• HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study.

  2016cites this paper
• 악골골수염 처치를 위한 조직공학적 접근

  2015cites this paper
• Beclin 1-Vps34 complex architecture: Understanding the nuts and bolts of therapeutic targets

  2015cites this paper
• Functional chromatographic technique for natural product isolation.

  2015cites this paper
• HPC Cloud Technologies for Virtual Screening in Drug Discovery

  2015cites this paper
• New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

  2015cites this paper
• Tissue Engineering Treatment in Osteomyelitis of the Jaws

  2015cites this paper
• Culture Models to Define Key Mediators of Cancer Matrix Remodeling

  2014cites this paper
• Identification of novel GSK1070916 analogs as potential aurora B inhibitors: insights from molecular dynamics and MM/GBSA based rescoring

  2014cites this paper
• Targeted therapies in oncology come of age.

  2013cites this paper